DE951551T1 - Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie - Google Patents
Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilieInfo
- Publication number
- DE951551T1 DE951551T1 DE0951551T DE97952609T DE951551T1 DE 951551 T1 DE951551 T1 DE 951551T1 DE 0951551 T DE0951551 T DE 0951551T DE 97952609 T DE97952609 T DE 97952609T DE 951551 T1 DE951551 T1 DE 951551T1
- Authority
- DE
- Germany
- Prior art keywords
- ligand
- kappa
- receptor activator
- tnf superfamily
- receptors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5997896P | 1996-12-23 | 1996-12-23 | |
US7718197P | 1997-03-07 | 1997-03-07 | |
US6467197P | 1997-10-14 | 1997-10-14 | |
PCT/US1997/023775 WO1998028426A2 (en) | 1996-12-23 | 1997-12-22 | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
Publications (1)
Publication Number | Publication Date |
---|---|
DE951551T1 true DE951551T1 (de) | 2000-09-14 |
Family
ID=27369779
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69740107T Expired - Lifetime DE69740107D1 (de) | 1996-12-23 | 1997-12-22 | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
DE69738841T Expired - Lifetime DE69738841D1 (de) | 1996-12-23 | 1997-12-22 | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
DE122010000048C Pending DE122010000048I1 (de) | 1996-12-23 | 1997-12-22 | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
DE0951551T Pending DE951551T1 (de) | 1996-12-23 | 1997-12-22 | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69740107T Expired - Lifetime DE69740107D1 (de) | 1996-12-23 | 1997-12-22 | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
DE69738841T Expired - Lifetime DE69738841D1 (de) | 1996-12-23 | 1997-12-22 | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
DE122010000048C Pending DE122010000048I1 (de) | 1996-12-23 | 1997-12-22 | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
Country Status (13)
Country | Link |
---|---|
US (21) | US6017729A (de) |
EP (5) | EP2003203A1 (de) |
JP (7) | JP2002509431A (de) |
AT (2) | ATE401404T1 (de) |
AU (2) | AU713471C (de) |
CA (1) | CA2274987C (de) |
DE (4) | DE69740107D1 (de) |
DK (1) | DK0951551T4 (de) |
ES (1) | ES2144386T5 (de) |
IL (1) | IL130492A (de) |
LU (1) | LU91758I2 (de) |
PT (1) | PT951551E (de) |
WO (2) | WO1998028424A2 (de) |
Families Citing this family (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050060764A1 (en) * | 2003-09-17 | 2005-03-17 | Susan Gregory | Mouse model for bone metabolism |
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US6919434B1 (en) | 1995-02-20 | 2005-07-19 | Sankyo Co., Ltd. | Monoclonal antibodies that bind OCIF |
US20050147611A1 (en) * | 1995-12-22 | 2005-07-07 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
US7632922B1 (en) * | 1995-12-22 | 2009-12-15 | Amgen, Inc. | Osteoprotegerin |
US6479254B2 (en) | 1996-03-22 | 2002-11-12 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US6495520B2 (en) | 1996-03-22 | 2002-12-17 | Human Genome Sciences, Inc. | Apoptosis Inducing Molecule II and methods of use |
AU5697098A (en) * | 1996-12-13 | 1998-07-03 | Schering Corporation | Mammalian cell surface antigens; related reagents |
EP2003203A1 (de) | 1996-12-23 | 2008-12-17 | Immunex Corporation | Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist |
CA2274803C (en) * | 1996-12-23 | 2012-05-22 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
HU229841B1 (en) * | 1997-04-15 | 2014-09-29 | Daiichi Sankyo Co Ltd | Antibodies against obm |
AU2008200700C1 (en) * | 1997-04-15 | 2013-04-04 | Daiichi Sankyo Co., Ltd | Novel Protein and Process for Producing The Same |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
WO1998046751A1 (en) * | 1997-04-16 | 1998-10-22 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
CA2229449A1 (en) * | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
AU7705098A (en) * | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
ATE328281T1 (de) | 1997-09-24 | 2006-06-15 | Sankyo Co | Methode zur diagnose von abnormalem knochenstoffwechsel |
US7063960B2 (en) | 1997-12-12 | 2006-06-20 | The Rockefeller University | Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
WO1999029865A2 (en) * | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
US7019119B2 (en) * | 1997-12-12 | 2006-03-28 | The Rockefeller University | Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
ATE517916T1 (de) * | 1998-05-14 | 2011-08-15 | Immunex Corp | Verfahren zur hemmung der wirkung der osteoklasten |
US20020106728A1 (en) * | 2000-06-20 | 2002-08-08 | Genentech, Inc. | NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders |
PT1114166E (pt) | 1998-09-15 | 2005-08-31 | Pharmexa A S | Metodo para regular negativamente a actividade do ligando da osteoprotegerina |
SI1114166T1 (en) * | 1998-09-15 | 2005-10-31 | Pharmexa A/S | Method for down-regulating osteoprotegerin ligand activity |
ES2421720T3 (es) | 1999-04-12 | 2013-09-05 | Genentech Inc | Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican |
US6492124B1 (en) | 1999-06-11 | 2002-12-10 | The Rockefeller University | Trance activated signal transduction pathways in osteoclasts |
US6872806B1 (en) * | 1999-06-25 | 2005-03-29 | The Governors Of The University Of Alberta | Polypeptide compositions formed using a coiled-coil template and methods of use |
KR100674528B1 (ko) | 1999-06-28 | 2007-01-29 | 제넨테크, 인크. | 2가 금속 이온을 사용한 Apo-2 리간드 제조 방법 |
US6673771B1 (en) | 1999-07-28 | 2004-01-06 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
JP4790179B2 (ja) * | 1999-07-28 | 2011-10-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア | 破骨細胞活性を阻害する方法 |
AUPQ314799A0 (en) * | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
US6171860B1 (en) * | 1999-11-05 | 2001-01-09 | Isis Pharmaceuticals, Inc. | Antisense inhibition of rank expression |
WO2001036637A1 (en) * | 1999-11-17 | 2001-05-25 | Immunex Corporation | Receptor activator of nf-kappa b |
GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
DK1255558T3 (da) | 2000-02-16 | 2006-10-23 | Genentech Inc | Anti-april antistoffer og hybridomaceller |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
EP1257648B2 (de) † | 2000-02-23 | 2016-09-14 | Amgen Inc. | Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
WO2001091793A1 (en) * | 2000-05-26 | 2001-12-06 | Smithkline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
ATE415978T1 (de) | 2000-07-27 | 2008-12-15 | Genentech Inc | Sequentielle verabreichung von cpt-11 und apo-2l polypeptid |
AU2001286586A1 (en) * | 2000-08-18 | 2002-03-04 | University Of Massachusetts Medical Center | Trance regulation of chondrocyte differentiation |
AU2001288342A1 (en) * | 2000-08-21 | 2002-03-04 | Smith Kline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
AU9303001A (en) * | 2000-09-22 | 2002-04-02 | Immunex Corp | Screening assays for agonists or antagonists of receptor activat or of nf-kb |
US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
EP1399555A2 (de) * | 2001-02-09 | 2004-03-24 | Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited | Rank-ligand-bindende polypeptide |
US20040132971A1 (en) * | 2001-02-09 | 2004-07-08 | Haaning Jesper Mortensen | Rank ligand-binding polypeptides |
US20030013651A1 (en) * | 2001-03-22 | 2003-01-16 | Barnes-Jewish Hospital | Stimulation of osteogenesis using rank ligand fusion proteins |
CA2441538A1 (en) * | 2001-03-22 | 2002-10-17 | Barnes-Jewish Hospital | Stimulation of osteogenesis using rank ligand fusion proteins |
US20050031583A1 (en) * | 2001-03-23 | 2005-02-10 | Iqbal Grewal | Uses of opg to modulate immune responses |
US20040167072A1 (en) * | 2001-05-11 | 2004-08-26 | Aggarwal Bharat B. | Inhibitors of receptor activator of NF-kappaB and uses thereof |
EP1385872A4 (de) * | 2001-05-11 | 2004-12-15 | Res Dev Foundation | Inhibitoren des rezeptor-aktivators von nf-kappa-b und deren verwendungen |
WO2002092016A2 (en) * | 2001-05-17 | 2002-11-21 | Immunex Corporation | Therapeutic use of rank antagonists |
US20040213788A1 (en) * | 2001-05-18 | 2004-10-28 | Sweet Raymond W. | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
MXPA03011270A (es) * | 2001-06-06 | 2004-03-18 | Immunex Corp | Uso de antagonistas rank para tratar cancer. |
PL222211B1 (pl) | 2001-06-26 | 2016-07-29 | Amgen Fremont Inc | Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza |
WO2003002187A2 (en) * | 2001-06-26 | 2003-01-09 | Photomed Technologies, Inc. | Multiple wavelength illuminator |
EP1409544B1 (de) | 2001-07-03 | 2009-06-17 | Genentech, Inc. | Humane dr4-antikörper und deren anwendungen |
US20030050223A1 (en) * | 2001-08-09 | 2003-03-13 | Jonathan Lam | Crystal forms and mutants of RANK ligand |
EP2348043A1 (de) | 2001-10-02 | 2011-07-27 | Genentech, Inc. | APO-2-Ligandvarianten und Verwendungen dafür |
CA2463478A1 (en) * | 2001-10-12 | 2003-08-14 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds |
US20030109444A1 (en) * | 2001-10-12 | 2003-06-12 | Jonathan Lam | Bone anti-resorptive compounds |
US20030100068A1 (en) * | 2001-10-12 | 2003-05-29 | Jonathan Lam | RANKL mimics and uses thereof |
IL161387A0 (en) * | 2001-10-15 | 2004-09-27 | Barnes Jewish Hospital | Rankl mimics and uses thereof |
EP1450847B1 (de) | 2001-11-13 | 2010-09-29 | Genentech, Inc. | Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung |
US7842668B1 (en) | 2001-11-13 | 2010-11-30 | Genentech, Inc. | Apo-2 ligand/trail formulations |
US7741285B2 (en) | 2001-11-13 | 2010-06-22 | Genentech, Inc. | APO-2 ligand/trail formulations |
US7381792B2 (en) * | 2002-01-04 | 2008-06-03 | Xencor, Inc. | Variants of RANKL protein |
US20040170602A1 (en) * | 2002-01-04 | 2004-09-02 | Desjarlais John R. | Dominant negative proteins and methods thereof |
EP1576088A4 (de) * | 2002-01-04 | 2006-09-06 | Xencor Inc | Dominant-negative proteine und verfahren dazu |
EP1560843A4 (de) * | 2002-01-04 | 2006-09-06 | Xencor Inc | Neue varianten von rankl-protein |
WO2003080671A1 (en) * | 2002-03-21 | 2003-10-02 | Komed Co., Ltd. | Anti-rank monoclonal antibodies and pharmaceutical composition containing the same |
PL375041A1 (en) | 2002-04-05 | 2005-11-14 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
CA2489348A1 (en) | 2002-06-24 | 2003-12-31 | Genentech, Inc. | Apo-2 ligand/trail variants and uses thereof |
US20040138162A1 (en) * | 2002-08-30 | 2004-07-15 | Roodman G. David | Method of resisting osteoclast formation |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
US7462700B2 (en) | 2002-12-10 | 2008-12-09 | Schering-Plough Animal Health Corporation | Canine RANKL and methods for preparing and using the same |
JP5253715B2 (ja) * | 2003-01-10 | 2013-07-31 | 株式会社プロテインクリスタル | タンパク質複合体及びその製造方法並びにその用途 |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7700574B2 (en) * | 2003-09-17 | 2010-04-20 | Isis Pharmaceuticals, Inc. | Modulation of RANKL expression |
US7252833B2 (en) * | 2003-11-18 | 2007-08-07 | Skeletal Kinetics, Llc | Calcium phosphate cements comprising an osteoclastogenic agent |
WO2005063170A2 (en) * | 2003-12-29 | 2005-07-14 | Toudai Tlo, Ltd. | Methods of identifying immunoregulatory agents, immunoregulatory agents, and uses thereof |
CN1980957A (zh) | 2004-03-23 | 2007-06-13 | 比奥根艾迪克Ma公司 | 受体偶联剂及其治疗用途 |
KR20130019457A (ko) | 2004-07-26 | 2013-02-26 | 다우 글로벌 테크놀로지스 엘엘씨 | 균주 조작에 의한 개선된 단백질 발현 방법 |
WO2006015373A2 (en) | 2004-08-04 | 2006-02-09 | Amgen Inc | Antibodies to dkk-1 |
KR101235479B1 (ko) | 2004-08-06 | 2013-02-20 | 제넨테크, 인크. | 바이오마커를 사용한 분석 및 방법 |
CN102978277A (zh) | 2004-08-06 | 2013-03-20 | 健泰科生物技术公司 | 使用生物标志的测定法和方法 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006059110A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
CA2619759A1 (en) | 2005-08-16 | 2007-02-22 | Genentech, Inc. | Apoptosis sensitivity to ap02l/trail by testing for galnac-t14 expression in cells/tissues |
CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
EP1854458A1 (de) * | 2006-05-08 | 2007-11-14 | IMBA-Institut für Molekulare Biotechnologie GmbH | Verwendung einer Verbindung mit RANKL Aktivität |
CA2651597C (en) | 2006-05-12 | 2013-02-05 | Keio University | Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease |
WO2008044379A1 (fr) | 2006-10-11 | 2008-04-17 | Oriental Yeast Co., Ltd. | Modèle animal de perte osseuse |
WO2008044797A1 (fr) | 2006-10-11 | 2008-04-17 | Oriental Yeast Co., Ltd. | Animal modèle d'ostéopénie |
WO2008044378A1 (fr) | 2006-10-11 | 2008-04-17 | Oriental Yeast Co., Ltd. | Réactif contenant une protéine fusionnée de rankl soluble avec un marqueur d'épitope |
CN101688213A (zh) | 2007-04-27 | 2010-03-31 | 陶氏环球技术公司 | 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法 |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
JP5191487B2 (ja) | 2007-06-05 | 2013-05-08 | オリエンタル酵母工業株式会社 | 新しい骨量増加薬 |
WO2008156865A2 (en) * | 2007-06-20 | 2008-12-24 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
CL2008002444A1 (es) | 2007-08-21 | 2009-09-04 | Amgen Inc | Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente. |
KR100911852B1 (ko) | 2007-11-26 | 2009-08-11 | 고려대학교 산학협력단 | 유세포 분석기를 이용한 신규한 rank와 rank리간드의 결합 분석방법 |
WO2009105934A1 (zh) * | 2008-02-27 | 2009-09-03 | 上海先导药业有限公司 | 抗人rankl单克隆抗体 |
CL2009001735A1 (es) | 2008-08-19 | 2010-02-19 | Regeneron Pharma | Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl |
US8657662B2 (en) | 2008-09-04 | 2014-02-25 | Patent Investment & Licensing Company | Gaming device having variable speed of play |
WO2010038610A1 (ja) | 2008-09-30 | 2010-04-08 | オリエンタル酵母工業株式会社 | 新しい軟骨細胞増殖及び分化誘導剤 |
CN101712964B (zh) * | 2008-10-08 | 2013-05-08 | 上海科新生物技术股份有限公司 | 抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物 |
NZ593643A (en) | 2008-11-25 | 2013-03-28 | Biogen Idec Inc | Use of dr6 and p75 antagonists to promote survival of cells of the nervous system |
CN101514232B (zh) * | 2009-03-25 | 2013-06-19 | 上海科新生物技术股份有限公司 | 一种RANKL-Fc融合蛋白及其制备方法和用途 |
EP2420515A4 (de) * | 2009-04-16 | 2013-08-28 | Univ Tokyo | Diagnose und behandlung von krebs mit anti-tmprss11e-antikörper |
KR101153393B1 (ko) * | 2009-09-21 | 2012-06-07 | 고려대학교 산학협력단 | 점변이 이용한 수용성 재조합 인간 rank의 효능 향상 및 골 질환 치료용 조성물 |
MX2013000301A (es) | 2010-07-09 | 2013-05-09 | Biogen Idec Hemophilia Inc | Factores quimericos de coagulacion. |
EP2434285A1 (de) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Brustkrebsdiagnose |
EP2433644A1 (de) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Brustkrebstherapeutika |
US10047398B2 (en) | 2010-10-06 | 2018-08-14 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
CA2831247C (en) | 2011-03-31 | 2020-07-21 | Oriental Yeast Co., Ltd. | Cancer immunopotentiating agent containing rankl antagonist |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
FR2980711A1 (fr) * | 2011-10-03 | 2013-04-05 | Centre Nat Rech Scient | Modulation du systeme immunitaire et des cellules stromales via rank |
EP2776066B1 (de) | 2011-11-07 | 2018-09-19 | Universite Laval | Rank-/rankl-antagonisten zur verwendung zur behandlung neuromuskulärer erkrankungen, genetischer myopathien und/oder nicht genetischer myopathien |
EP2650682A1 (de) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Asymmetrische Ester von als Schmiermittel geeigneten Fettsäuren |
CA2875918A1 (en) | 2012-06-06 | 2013-12-12 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
KR101872965B1 (ko) | 2012-10-12 | 2018-06-29 | 인바이오모션 에스.엘. | C―maf를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법 |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
JP6577873B2 (ja) | 2013-03-15 | 2019-09-18 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ(イエレベ、バルセロナ)Fundacio Institut De Recerca Biomedica (Irb Barcelona) | がんの転移の予後診断および処置のための方法 |
US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
CA2920376A1 (en) | 2013-08-07 | 2015-02-12 | Martin Blomberg JENSEN | Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility |
WO2015030701A1 (en) * | 2013-08-24 | 2015-03-05 | R-Pharm Overseas, Inc. | Fully human antibodies against human rankl |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
EP3712166A1 (de) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen |
CN105980576B (zh) | 2013-10-09 | 2021-07-16 | 生物医学研究机构基金会 | 用于源自乳腺癌的骨转移癌的预后和治疗的方法 |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
WO2015175861A1 (en) | 2014-05-16 | 2015-11-19 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
CN104829725A (zh) * | 2015-01-21 | 2015-08-12 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd133×cd3的构建及应用 |
EP4039253A1 (de) | 2015-04-29 | 2022-08-10 | Radius Pharmaceuticals, Inc. | Verfahren zur behandlung von krebs |
BR112017020610A2 (pt) | 2015-05-18 | 2018-07-17 | Lilly Co Eli | Compostos de anticorpo biespecífico anti-dkk-1- anti-rankl |
CN108064231A (zh) * | 2015-05-20 | 2018-05-22 | 国立大学法人大阪大学 | 具有炎性细胞因子分泌抑制活性的寡肽 |
WO2017120349A1 (en) * | 2016-01-05 | 2017-07-13 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for regulating activity of inhibitor of dna binding-2 (id2) protein |
WO2017123642A1 (en) * | 2016-01-12 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis |
AU2017214277B2 (en) | 2016-02-01 | 2020-02-27 | Eli Lilly And Company | Parathyroid hormone – anti-RANKL antibody fusion compounds |
MA43814A (fr) | 2016-03-08 | 2018-11-28 | Janssen Biotech Inc | Anticorps anti-gitr, méthodes et utilisations |
AU2017271385B2 (en) | 2016-05-25 | 2023-10-05 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
MX2019004862A (es) | 2016-10-28 | 2019-08-12 | Lilly Co Eli | Anticuerpos anti-rankl y usos de los mismos. |
EP3565542B1 (de) | 2017-01-05 | 2024-04-10 | Radius Pharmaceuticals, Inc. | Polymorphe formen von rad1901-2hcl |
AU2018235928B2 (en) | 2017-03-14 | 2023-09-21 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
US11654153B2 (en) | 2017-11-22 | 2023-05-23 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
MA52186A (fr) | 2018-03-26 | 2021-02-17 | Amgen Inc | Glycoformes afucosylées totales d'anticorps produits en culture cellulaire |
JP7473486B2 (ja) | 2018-07-04 | 2024-04-23 | ラジウス ファーマシューティカルズ,インコーポレイテッド | Rad1901-2hclの多形形態 |
WO2020070288A1 (en) | 2018-10-05 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
EP3883610A4 (de) | 2018-11-20 | 2022-11-02 | Cornell University | Makrocyclische komplexe von radionukliden und deren verwendung in der radiotherapie von krebs |
WO2021062372A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
EP4110371A1 (de) | 2020-01-24 | 2023-01-04 | Radius Health, Inc. | Verfahren zur stimulierung des knochenwachstums mit abalopartid und denosumab |
CN111793135A (zh) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | 一种用于检测血清中rankl含量的抗体对及其用途 |
EP4162257A1 (de) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Beurteilung von reinigungsvorgängen eines biotherapeutischen herstellungsverfahrens |
EP4229080A1 (de) | 2020-10-15 | 2023-08-23 | Amgen Inc. | Relative ungepaarte glycane in antikörperherstellungsverfahren |
EP4352094A1 (de) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Verwendung von fucosidase zur steuerung des afucosylierungsniveaus glykosylierter proteine |
WO2023059607A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023179791A1 (en) * | 2022-03-24 | 2023-09-28 | Angitia Biomedicines Limited | Treatment of musculoskeletal disorders |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4710457A (en) | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
US4710473A (en) | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
EP0192658A4 (de) | 1984-07-30 | 1987-07-13 | Salk Inst For Biological Studi | Retrovirale gentransfervektoren. |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
JP2598801B2 (ja) * | 1986-07-18 | 1997-04-09 | ザ ユニバーシティー オブ メルボルン | 悪性‐PTHrPの液性過カルシウム血症において活性なタンパク |
US5846534A (en) | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2071912C (en) | 1990-11-30 | 2002-10-15 | Hanne Bentz | Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair |
US6121002A (en) * | 1990-12-26 | 2000-09-19 | The Rowett Research Institute | Method to detect bone and other connective tissue disorders in humans and animals |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
CA2068389A1 (en) | 1991-05-13 | 1992-11-14 | Masahiko Sato | Method for inhibiting bone resorption |
MX9204303A (es) | 1991-07-23 | 1993-11-01 | Rhone Poulenc Rorer Int | Factor regulador del crecimiento de osteoclasto. |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
ATE239790T1 (de) * | 1991-10-25 | 2003-05-15 | Immunex Corp | Antikörper gegen cd40-l |
US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
DK0639079T3 (da) | 1992-04-30 | 2000-06-13 | Amgen Inc | Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US5578569A (en) | 1993-03-12 | 1996-11-26 | Tam; Cherk S. | Method of increasing bone growth |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
ES2157991T3 (es) | 1993-09-14 | 2001-09-01 | Merck & Co Inc | Cadn que codifica una nueva proteina humana, la tirosin-fosfatasa. |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
US5741667A (en) | 1994-05-27 | 1998-04-21 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
AU4440496A (en) | 1995-02-10 | 1996-08-22 | Smithkline Beecham Corporation | Use of src SH2 specific compounds to treat a bone resorption disease |
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US20030166097A1 (en) | 1995-03-15 | 2003-09-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
WO1996028546A1 (en) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US7094564B1 (en) | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
JPH11507205A (ja) | 1995-04-27 | 1999-06-29 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子受容体 |
WO1997000317A1 (en) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Osteoclast growth regulatory factor |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
AU6090896A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
IL122174A (en) | 1995-06-07 | 2004-07-25 | Immunex Corp | DNA encoding the CD40L mutine and CD40L polypeptide encoded by the above DNA |
US5763223A (en) * | 1995-06-29 | 1998-06-09 | Immunex Corporation | DNA encoding a cytokine that induces apoptosis |
ZA966663B (en) | 1995-08-17 | 1998-02-06 | Genentech Inc | Traf Inhibitors. |
JPH0997808A (ja) | 1995-09-29 | 1997-04-08 | Mitsumi Electric Co Ltd | ダイボンディング装置 |
JPH09151434A (ja) | 1995-11-24 | 1997-06-10 | Tootetsu:Kk | 角形蛇籠の変形防止枠及びその蛇籠の設置方法 |
US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
PT873405E (pt) | 1996-01-11 | 2005-01-31 | Immunex Corp | Elementos de sequencia que aumentam a expressao (ease) para sistemas de expressao eucarioticos |
JPH09217897A (ja) | 1996-02-14 | 1997-08-19 | Hitachi Ltd | Sf6貯蔵供給装置、その貯蔵方法及び供給方法 |
JPH09224803A (ja) | 1996-02-21 | 1997-09-02 | Nakajima Cafe Honsha:Kk | 蓋付きコーヒーカップ |
US5766223A (en) | 1996-03-21 | 1998-06-16 | Johnson; Deborah M. | Child's teething device |
US5710013A (en) | 1996-04-19 | 1998-01-20 | Tularik Inc. | Tumor necrosis factor receptor associated factor 6 (TRAF6) |
JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規dna及びそれを用いた蛋白質の製造方法 |
AU5697098A (en) | 1996-12-13 | 1998-07-03 | Schering Corporation | Mammalian cell surface antigens; related reagents |
WO1998028423A2 (en) * | 1996-12-20 | 1998-07-02 | Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
EP2003203A1 (de) | 1996-12-23 | 2008-12-17 | Immunex Corporation | Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist |
US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
HU229841B1 (en) | 1997-04-15 | 2014-09-29 | Daiichi Sankyo Co Ltd | Antibodies against obm |
WO1998046751A1 (en) | 1997-04-16 | 1998-10-22 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
CA2229449A1 (en) * | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
CA2288351A1 (en) | 1997-05-01 | 1998-11-05 | Amgen Inc. | Chimeric opg polypeptides |
AU7705098A (en) | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
US6087555A (en) | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
US7019119B2 (en) * | 1997-12-12 | 2006-03-28 | The Rockefeller University | Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
US7063960B2 (en) * | 1997-12-12 | 2006-06-20 | The Rockefeller University | Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
JPH11266872A (ja) * | 1998-03-20 | 1999-10-05 | Suntory Ltd | NF−κBの活性化を抑制する物質のスクリーニング方法 |
US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
ATE517916T1 (de) | 1998-05-14 | 2011-08-15 | Immunex Corp | Verfahren zur hemmung der wirkung der osteoklasten |
HUP0102492A2 (hu) | 1998-06-19 | 2001-11-28 | Smithkline Beecham Corp. | Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására |
HUP0102782A3 (en) | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
WO2001003719A2 (en) | 1999-07-09 | 2001-01-18 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
US6252180B1 (en) * | 1999-08-09 | 2001-06-26 | Lucent Technologies Inc. | Electromagnetic interference cover for a conduit and an electronic equipment chassis employing the same |
IL142900A0 (en) | 1999-09-03 | 2002-04-21 | Amgen Inc | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
US20030144187A1 (en) | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
AUPQ314799A0 (en) | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
EP1257648B2 (de) | 2000-02-23 | 2016-09-14 | Amgen Inc. | Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins |
US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
AU2001288342A1 (en) * | 2000-08-21 | 2002-03-04 | Smith Kline Beecham Corporation | Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
PL222211B1 (pl) | 2001-06-26 | 2016-07-29 | Amgen Fremont Inc | Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza |
PL375041A1 (en) | 2002-04-05 | 2005-11-14 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
US7157993B2 (en) | 2003-09-30 | 2007-01-02 | Rockwell Scientific Licensing, Llc | 1:N MEM switch module |
-
1997
- 1997-12-22 EP EP08010882A patent/EP2003203A1/de not_active Withdrawn
- 1997-12-22 ES ES97952609T patent/ES2144386T5/es not_active Expired - Lifetime
- 1997-12-22 WO PCT/US1997/023866 patent/WO1998028424A2/en active IP Right Grant
- 1997-12-22 DE DE69740107T patent/DE69740107D1/de not_active Expired - Lifetime
- 1997-12-22 IL IL130492A patent/IL130492A/en not_active IP Right Cessation
- 1997-12-22 JP JP52906898A patent/JP2002509431A/ja not_active Withdrawn
- 1997-12-22 EP EP10182863A patent/EP2314695A3/de not_active Withdrawn
- 1997-12-22 WO PCT/US1997/023775 patent/WO1998028426A2/en active Application Filing
- 1997-12-22 DE DE69738841T patent/DE69738841D1/de not_active Expired - Lifetime
- 1997-12-22 DE DE122010000048C patent/DE122010000048I1/de active Pending
- 1997-12-22 JP JP52904598A patent/JP4138013B2/ja not_active Expired - Lifetime
- 1997-12-22 US US08/996,139 patent/US6017729A/en not_active Expired - Lifetime
- 1997-12-22 AT AT97952609T patent/ATE401404T1/de active
- 1997-12-22 EP EP97952609A patent/EP0951551B9/de not_active Expired - Lifetime
- 1997-12-22 EP EP10182860A patent/EP2371962A3/de not_active Withdrawn
- 1997-12-22 EP EP97953438A patent/EP0946725B1/de not_active Expired - Lifetime
- 1997-12-22 AU AU56180/98A patent/AU713471C/en not_active Expired
- 1997-12-22 AT AT97953438T patent/ATE497001T1/de active
- 1997-12-22 PT PT97952609T patent/PT951551E/pt unknown
- 1997-12-22 DK DK97952609.2T patent/DK0951551T4/da active
- 1997-12-22 AU AU57184/98A patent/AU713473B2/en not_active Ceased
- 1997-12-22 CA CA2274987A patent/CA2274987C/en not_active Expired - Lifetime
- 1997-12-22 US US08/995,659 patent/US6242213B1/en not_active Expired - Lifetime
- 1997-12-22 DE DE0951551T patent/DE951551T1/de active Pending
-
1999
- 1999-12-17 US US09/466,496 patent/US6528482B1/en not_active Expired - Lifetime
-
2000
- 2000-05-24 US US09/577,800 patent/US6479635B1/en not_active Expired - Lifetime
- 2000-05-24 US US09/577,780 patent/US6419929B1/en not_active Expired - Lifetime
- 2000-10-13 US US09/688,459 patent/US6838262B1/en not_active Expired - Lifetime
-
2001
- 2001-05-25 US US09/865,363 patent/US6740522B2/en not_active Expired - Lifetime
- 2001-05-30 US US09/871,291 patent/US6562948B2/en not_active Expired - Fee Related
- 2001-05-31 US US09/871,856 patent/US6537763B2/en not_active Expired - Fee Related
- 2001-06-08 US US09/877,650 patent/US6649164B2/en not_active Expired - Lifetime
-
2003
- 2003-04-01 US US10/405,878 patent/US7262274B2/en not_active Expired - Fee Related
-
2004
- 2004-03-16 US US10/802,133 patent/US7411050B2/en not_active Expired - Fee Related
-
2006
- 2006-07-26 JP JP2006203204A patent/JP4054354B2/ja not_active Expired - Lifetime
-
2007
- 2007-07-30 US US11/881,911 patent/US7932375B2/en not_active Expired - Fee Related
- 2007-10-12 JP JP2007266393A patent/JP4203105B2/ja not_active Expired - Lifetime
-
2008
- 2008-02-25 JP JP2008043360A patent/JP4242913B2/ja not_active Expired - Lifetime
- 2008-06-24 US US12/214,914 patent/US7744886B2/en not_active Expired - Fee Related
- 2008-11-11 JP JP2008288844A patent/JP2009051862A/ja not_active Withdrawn
-
2010
- 2010-06-15 US US12/802,801 patent/US8377690B2/en not_active Expired - Fee Related
- 2010-07-02 JP JP2010152282A patent/JP5096527B2/ja not_active Expired - Lifetime
- 2010-08-04 US US12/850,368 patent/US8333963B2/en not_active Expired - Fee Related
- 2010-11-24 LU LU91758C patent/LU91758I2/fr unknown
-
2011
- 2011-04-22 US US13/092,718 patent/US8153775B2/en not_active Expired - Fee Related
-
2012
- 2012-03-19 US US13/424,179 patent/US8569456B2/en not_active Expired - Fee Related
-
2013
- 2013-02-12 US US13/765,597 patent/US8715683B2/en not_active Expired - Fee Related
- 2013-10-28 US US14/065,133 patent/US20140186887A1/en not_active Abandoned
-
2014
- 2014-05-02 US US14/268,858 patent/US20140235832A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69738841D1 (de) | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie | |
ATE187982T1 (de) | Cytokine antagoniste | |
DE69633617D1 (de) | Il-17 receptor | |
DK0760857T3 (da) | Receptor for onkostatin M | |
DE3482107D1 (de) | Zementzusammensetzungen und zementierungsverfahren in oelgebieten. | |
ATE114724T1 (de) | Antikörper gegen tnf-bindungsprotein i und deren f(ab)-fragmente. | |
DE69207351T2 (de) | Fibrinogen-Rezeptor-Antagoniste | |
DE69033210T2 (de) | (Modifiziertes) hydriertes Dien-Blockcopolymer und dieses enthaltende Zusammensetzung | |
DE69327720D1 (de) | Endothelin rezeptor antagonisten | |
DE69331175D1 (de) | Interleukin-2 Rezeptor Gamma-Kette | |
IT1228211B (it) | Agglomerato combustibile resistente all'acqua, procedimento per la sua preparazione e composizione di materiali usata in tale procedimento. | |
DE58909630D1 (de) | Photopolymerisierbares Gemisch und dieses enthaltendes photopolymerisierbares Aufzeichnungsmaterial | |
FR2695475B1 (fr) | Conductivimètre pour mesurer en régime transitoire la conductivité d'un matériau injectable ou non. | |
NO179550C (no) | Tachykinin reseptorantagonister | |
DE58907320D1 (de) | Bituminöse Masse und deren Verwendung. | |
IT1223336B (it) | Composizione bituminosa e suo impiego nel settore dell'impermeabilizzazione | |
IT8948295A0 (it) | Procedimento ed apparecchio per la cernita di materiali particellari mediante attrito | |
DE69003364D1 (de) | Einrichtung zum Einfahren von Gewindeverbindungen für Rohrstränge durch Festschrauben und Losdrehen. | |
ITRM920415A0 (it) | Composizione per uso chirurgico e sua applicazine per irrigazioni chirurgiche. | |
ES295315U (es) | Dispositivo de anclaje a barandillas perfeccionado, para porta-jardineras y similares | |
DK410789D0 (da) | Indretning til sneplov | |
IT1161553B (it) | Materiali minerali granulari stabilizzati per impieghi in mantichiari e riflettenti per strade,piste e simili,e procedimento per ottenerli |